Recent share performance context

Novo Nordisk (NYSE:NVO) has been on many investors’ radar after a period of mixed share performance, with the stock down over the past month but higher over the past 3 months.

At a last close of US$41.02, the stock is also lower over the year to date and the past year, while the 5 year total return remains positive. This gives investors a wide range of recent return experiences to consider.

Short term momentum has cooled, with the share price down 10.96% over the past month and 21.70% year to date. The 5 year total shareholder return of 4.78% is still positive, so recent moves may reflect shifting views on Novo Nordisk’s growth potential and risk profile rather than a simple break in its longer term story.

If you are weighing Novo Nordisk against other opportunities in healthcare, this could be a good moment to scan for companies harnessing AI in medicine through our 39 healthcare AI stocks

With the share price weaker over the past year but a 5 year return still in positive territory, the real question is whether Novo Nordisk is now trading below its underlying potential, or if the market already reflects future growth.

Most Popular Narrative: 56.8% Undervalued

According to one of the most followed narratives on Novo Nordisk, a fair value of $95 per ADR sits well above the recent close of $41.02, pointing to a large valuation gap that some investors are watching closely.

Novo Nordisk (NVO) has continued to face a tougher near-term backdrop, but the longer-term investment case remains intact. Management has narrowed 2025 guidance to 8 to 11% sales growth and 4 to 7% operating profit growth (constant exchange rates), explicitly citing intensifying competition and pricing pressure in both diabetes and obesity.

The fair value hinges on how this narrative treats GLP-1 demand, margins under pricing pressure, and the role of oral Wegovy as a volume catalyst. The assumptions behind those moving parts are where the story really gets interesting.

Result: Fair Value of $95 (UNDERVALUED)

However, this hinges on GLP-1 momentum holding up, and policy or pricing shifts on key semaglutide products could quickly weaken the undervalued narrative.

Next Steps

With mixed signals on valuation, risks and rewards, this is a good time to review the data yourself and decide how the story fits into your own portfolio using our breakdown of 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you may miss opportunities that fit your style even better. Use the screeners below to widen your net.

• Spot potential mispricings early by scanning a focused set of companies that screens for 47 high quality undervalued stocks.
• Prioritize resilience by filtering for 63 resilient stocks with low risk scores that aim to keep portfolio swings more controlled.
• Get ahead of the crowd by searching a screener containing 21 high quality undiscovered gems before they hit the mainstream radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.